



Cedars-Sinai Biomanufacturing Center
Certificate of Analysis (COA)

Cell Line Name	CS83iCTR-33n1
CS Vial ID #(s)	VIAL ID
Date Viald	2/17/2023
Passage Number	15

The following testing specifications have been met for the specified cell line:

Test Description	Test Specification	Result
Mycoplasma	No contamination detected	Pass
Alkaline Phosphatase Staining	Positive AP staining	Pass
Karyotype by G-Banding	Normal Karyotype	Pass
Pluripotency		
<i>PrimeView Global Gene Expression Profile Assay (PluriTest)</i>	Pluripotency score ≥ 20 and novelty score ≤ 1.6	Pass
<i>Immunocytochemistry (IF-IC)</i>	OCT3/4, NANOG, SOX2, TRA-1-60, TRA-1-81, SSEA4	Pass
TaqMan® hPSC Scorecard™ Assay	Confirm appropriate expression of self-renewal factors	N/A
Differentiation		
<i>EB Formation</i>	Successful Embryoid Body (EB) formation after 14 days	Pass
TaqMan® hPSC Scorecard™ Assay or Differentiation PCR	Tri-lineage differentiation potential <i>Endoderm, Ectoderm and Mesoderm</i>	Pass
Reprogramming Plasmid Integration		
<i>Genomic DNA PCR</i>	Confirm the presence or absence of exogenous reprogramming plasmids	Absent
Parent Cell Line Lineage Determination		
TCRB + TCRG T-Cell Clonality Assay <i>(Blood derived cell lines only)</i>	Confirm presence or absence of clonal T-cell receptor beta chain and gamma chain gene rearrangements in iPSCs	N/A
Cell Line Authentication		
STR Analysis	Confirm identity matching score is above 80%	Confirmed

Dhruv Sareen, Ph.D; CS Biomanufacturing Ctr.

Dhruv Sareen, Ph.D

Executive Director, Cedars-Sinai Biomanufacturing Center



CONTACT INFORMATION:

Executive Director:
Dhruv Sareen, Ph.D.

Institution:
Cedars-Sinai Biomanufacturing Center

Phone Number:
(310) 423-3400

Address:
8687 Melrose Ave
Suite B227

Email Address:
GroupiPSCOrders@cshs.org

West Hollywood, CA 90069
USA

PARENT LINE IDENTIFICATION AND INFORMATION:

Parent Cell Line: GM02183

Age at Tissue Sampling: 21

Phenotypic Sex: ☐ Male ☒ Female

Clinical Diagnosis (if known): Clinically Normal

Specific Mutations (if known): 33 CAG repeats

Additional Information: At risk (50%) for Huntington's Disease

REPROGRAMMING INFORMATION:

iPSC Line Name: CS83iCTR-33n1

Vial ID(s): VIAL ID

Starting Cell Type: ☐ PBMC ☒ Fibroblast ☐ Other:

Reprogramming Method: ☒ Episomal ☐ Sendai Virus ☐ Other:

Reprogramming Factors: ☒ Oct3/4 ☒ Sox2 ☒ KLF4 ☒ L-Myc ☒ shp53 ☒ Lin28

☐ Other:

CULTURING INFORMATION:

MEDIUM:

Growth Medium: mTeSR Plus

Company: StemCell Technologies

Catalog #: 100-0276



SUBSTRATE:

Substrate Specification: Cultrex UltiMatrix RGF Basement Membrane Extract

Company: R&D Systems

Catalog #: BME001-10

Coating Concentration: 1.0mg per 6-well plate or 0.16mg per well

PASSAGING METHOD:

Method:

STEMPRO EZPassage Tool	Versene (EDTA)	ReLeSR
7 days	7 days	7 days
		1:12
☐	☐	☒

Passaging Frequency: 7 days

Average Split Ratio: 1:12

Cell Line Preferred Method: ☐ ☐ ☒

Rate of Differentiation: ☐ High ($\geq 50\%$) ☐ Moderate (30-40%) ☒ Low ($\leq 20\%$)

Freezing Media: Cryostor CS10

Recovery Media: mTeSR Plus

CHARACTERIZATION OF UNDIFFERENTIATED PLURIPOTENT CELL LINE:

G-BAND KARYOTYPE:

Performed By: Cedars-Sinai Department of Pathology and Laboratory Medicine

Passage Number: 25

Karyotyping Analysis & Results: 46,XX

Interpretation: Normal Female Karyotype

Comments:

Cytogenetic analysis using G-banding at or below the 400 band level of resolution on slides of these cultured cells revealed a 46,XX normal female karyotype. No consistent numerical or structural abnormality was observed, and there was no demonstrable clinically significant abnormality.

PLURITEST:

Final Result: ☒ Pass ☐ Fail ☐ Further Evaluate ☐ TBD ☐ N/A

Pluripotency Score, Pass >20 : 30.17

Novelty Score, Pass <1.6 : 1.342



IMMUNOCYTOCHEMISTRY:

Pluripotency Marker:

AP	SSEA-4	Tra-1-60	Tra-1-81	Nanog	Oct4	Sox2
☒	☒	☒	☒	☒	☒	☒

PLASMID INTEGRATION ANALYSIS:

Absence of plasmid integration confirmed by gDNA PCR:

Result:

EBNA Negative	EBNA Positive	TBD	N/A
☒	☐	☐	☐

Passage #:

Unknown

CHARACTERIZATION OF DIFFERENTIATION POTENTIAL:

This cell line has been assessed for differentiation potential by:

☒ 14 Day Embryoid Body Formation ☐ TaqMan® hPSC Scorecard™ Assay ☒ PCR ☐ N/A

hPSC SCORECARD DATA ANALYSIS:

iPSC (Day 0):

Score:

EBs (Day 14):

Score:

Self-Renewal	Ectoderm	Mesoderm	Endoderm
N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A

Comments:

In lieu of the hPSC Scorecard, embryoid body differentiation was assessed by PCR. PCR analysis confirmed gene expression of all three germ layers for Day 14 EBs as follows:
Endoderm: AFP
Ectoderm: NCAM
Mesoderm: MSX, HAND

PARENT CELL LINE LINEAGE DETERMINATION:

(Blood derived cell lines only)

T-Cell Clonality Assay:

TCR- $\alpha\beta$		TCR- $\gamma\delta$	
☐ Positive	☐ Negative	☐ Positive	☐ Negative

Final Result:

☐ T-Cell Derived ☐ Non T-Cell Derived ☐ TBD ☒ N/A



CELL LINE AUTHENTICATION:

Parent Cell Line: GM02183

AMEL	CSF1PO	D13S317	D16S539	D5S818	D7S820	TH01	TPOX	vWA
X	12	14	11	11, 12	8, 12	9, 9.3	8	16, 19

iPSC Line: CS83iCTR-33n1

AMEL	CSF1PO	D13S317	D16S539	D5S818	D7S820	TH01	TPOX	vWA
X	12	14	11	11, 12	8, 12	9, 9.3	8	16, 19

% Identity Match: 100%

IDEXX IBR #(s): 3020-2020 #19

ADDITIONAL INFORMATION:

FACS Analysis:

% OCT4 Positive: 96.8%

% SSEA4 Positive: 99.5%

% Double Positive: 97.9%



qRT-PCR analysis confirmed the endogenous pluripotency gene expression for OCT3/4 (POU5F1), SOX2, LIN28, KLF4, L-Myc.

qRT-PCR analysis confirmed lack of exogenous gene expression.



83iCTR-33n1 P25




CS83iCTR-33n1	
Alkaline Phosphatase Staining	
Oct4/SSEA4/DAPI	



CS83iCTR-33n1

SOX2/TRA-1-81/DAPI



NANOG/TRA-1-60/DAPI

